Clinical Trials · NCT06269107
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 485
- Start date
- Feb 2024
- Locations
- 118 sites, 10 countries
- Primary endpoint
- Change in glycated haemoglobin (HbA1c)